Chroman 1
Based on 70 publication(s) in Google Scholar
Chroman 1 is a highly potent and selective ROCK inhibitor. Chroman 1 is more potent against ROCK2 (IC50=1 pM) than ROCK1 (IC50=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC50 of 150 nM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.97%
- CAS 番号: 1273579-40-0
- 分子式: C24H28N4O4
- 分子量:436.50
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
MedChemExpress(MCE)の使用を引用している文献 Chroman 1
More- Nature. 2024 Feb;626(8000):874-880. [Abstract]
- Cell. 2026 Jan 8;189(1):70-86.e20. [Abstract]
- Nat Methods. 2025 Nov 28. [Abstract]
- Nat Methods. 2021 May;18(5):528-541. [Abstract]
- Immunity. 2024 Dec 6:S1074-7613(24)00513-2. [Abstract]
- Cell Stem Cell. 2025 Oct 2;32(10):1509-1527.e9. [Abstract]
- Mol Cell. 2023 Jul 20;83(14):2398-2416.e12. [Abstract]
- ACS Nano. 2025 Oct 26. [Abstract]
- Nat Protoc. 2023 Jan;18(1):58-80. [Abstract]
- Nat Commun. 2025 May 28;16(1):4945. [Abstract]
- Exp Hematol Oncol. 2025 Mar 1;14(1):26. [Abstract]
- Nat Struct Mol Biol. 2026 Apr;33(4):631-640. [Abstract]
- Acta Neuropathol. 2024 Mar 13;147(1):56. [Abstract]
- Cell Rep. 2025 Jul 10;44(7):115961. [Abstract]
- Cell Rep. 2025 May 20;44(6):115707. [Abstract]
- Cell Rep. 2023 Aug 30;42(9):113046. [Abstract]
- Bioeng Transl Med. 2025 Sep 22.
- Stem Cell Reports. 2023 Apr 11;18(4):1030-1047. [Abstract]
- Cell Regen. 2025 Jan 8;14(1):1. [Abstract]
- Bioorg Chem. 2024 Jun:147:107412. [Abstract]
- J Med Virol. 2024 Apr;96(4):e29579. [Abstract]
- Cell Rep Methods. 2024 Aug 27:100843. [Abstract]
- iScience. 2026 Jun 1;29(6):116143. [Abstract]
- iScience. 2024 Sep 3;27(10):110874. [Abstract]
- Sci Rep. 2025 Dec 24;15(1):44450. [Abstract]
- Dis Model Mech. 2026 Jun 1;19(6):dmm052511. [Abstract]
- Cytotherapy. 2024 Jun;26(6):556-566. [Abstract]
- Mol Biol Cell. 2025 Dec 3:mbcE25060300. [Abstract]
- Regen Med. 2023 Mar;18(3):219-227. [Abstract]
- STAR Protoc. 2025 Oct 13;6(4):104142. [Abstract]
- STAR Protoc. 2024 Dec 20;6(1):103532. [Abstract]
- STAR Protoc. 2022 Dec 16;3(4):101847. [Abstract]
- bioRxiv. 2026 Jun 18:2026.06.16.732780. [Abstract]
- bioRxiv. 2026 Jun 1:2026.05.31.729073. [Abstract]
- bioRxiv. 2026 Jun 24.
- bioRxiv. 2026 Apr 1:2026.03.31.715684. [Abstract]
- University of Bonn. 2026.
- bioRxiv. 2026 Mar 1:2026.02.27.708613. [Abstract]
- bioRxiv. 2026 Feb 16:2026.02.13.705790. [Abstract]
- bioRxiv. 2026 Feb 24.
- bioRxiv. 2026 Jan 15:2026.01.14.699349. [Abstract]
- bioRxiv. 2026 Jan 23.
- bioRxiv. 2025 Nov 18.
- bioRxiv. 2025 Nov 6:2025.11.05.685987. [Abstract]
- bioRxiv. 2025 Nov 18.
- Res Sq. 2025 Oct 16.
- bioRxiv. 2025 Oct 8:2025.10.07.681020. [Abstract]
- City University of New York. 2025.
- bioRxiv. 2025 Sep 3:2025.09.02.672952. [Abstract]
- bioRxiv. 2025 Sep 30.
- bioRxiv. 2025 Jul 14:2025.06.22.660773. [Abstract]
- bioRxiv. 2025 May 26.
- bioRxiv. 2025 Feb 19:2025.02.18.638932. [Abstract]
- bioRxiv. 2025 Mar 26:2025.03.25.645331. [Abstract]
- bioRxiv. 2025 Mar 17:2025.03.17.643709. [Abstract]
- bioRxiv. 2024 Sep 27:2024.09.26.615153. [Abstract]
- bioRxiv. 2024 Dec 4:2024.12.03.626438. [Abstract]
- bioRxiv. 2025 Jun 30:2024.09.30.615241. [Abstract]
- bioRxiv. 2024 Dec 11:2024.10.01.616167. [Abstract]
- bioRxiv. 2024 Jul 24:2024.07.24.604966. [Abstract]
- SSRN. 2024 Jun 05.
- protocols.io. 2024 Apr 4.
- bioRxiv. 2024 Feb 7.
- Res Sq. 2023 Oct 19:rs.3.rs-3462973. [Abstract]
- Res Sq. 2023 Aug 22:rs.3.rs-3260870. [Abstract]
- Methods Mol Biol. 2024:2767:1-18. [Abstract]
- protocols.io. 2023 Jun 6.
- bioRxiv. November 19, 2021.
- Methods Mol Biol. 2022:2454:811-827. [Abstract]
- bioRxiv. 2020 Aug 3:2020.08.03.235242. [Abstract]
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
WB
生物活性
|
ROCK2 1 pM (IC50) |
ROCK1 52 pM (IC50) |
MRCK 150 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A7R5 | IC50 |
<4 nM
Compound: (S)-1
|
Inhibition of ROCK2-mediated myosin light chain bis-phosphorylation in rat A7r5 cells after 1 hr by TO-PRO-3 iodide staining-based assay
Inhibition of ROCK2-mediated myosin light chain bis-phosphorylation in rat A7r5 cells after 1 hr by TO-PRO-3 iodide staining-based assay
|
10.1039/C0MD00194E |
Chroman 1 (50 nM, 24 h) inhibits caspase-3/7 activation and reduces apoptosis in human pluripotent stem cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:hESCs (human pluripotent stem cells) (WA09)
-
Concentration:50 nM
-
Incubation Time:0-12 h or 24 h
-
Result:Reduced the number of apoptotic cells, reduced caspase-3/7 activation.
-
Cell Line:hESCs (human pluripotent stem cells) (WA09)
-
Concentration:50 nM
-
Incubation Time:24 h
-
Result:Partially inhibited caspase-3 activation.
化学情報
-
CAS 番号 1273579-40-0
-
性状 Solid
-
分子量 436.50
-
分子式 C24H28N4O4
-
Color White to pink
-
SMILES
O=C([C@@H]1COC2=CC=C(OC)C=C2C1)NC3=CC=C(C4=CNN=C4)C=C3OCCN(C)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (70)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Feb;626(8000):874-880. PMID: 38297121 -
Cell
2026 Jan 8;189(1):70-86.e20. PMID: 41443192 -
Nat Methods
ExoSloNano: multimodal nanogold labels for identification of macromolecules in live cells and cryo-electron tomograms. [Abstract]2025 Nov 28. PMID: 41315814 -
Nat Methods
A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. [Abstract]2021 May;18(5):528-541. PMID: 33941937
Chroman 1 purchased from MedChemExpress. Usage Cited in: Nat Methods. 2021 May;18(5):528-541. [Abstract]
Improved survival of hESCs (WA09) with Chroman 1 (50 nM; 24 h) treatment.
Chroman 1 purchased from MedChemExpress. Usage Cited in: Nat Methods. 2021 May;18(5):528-541. [Abstract]
Chroman 1 (50 nM; 24 h). hESCs (WA09) cells were dissociated with Accutase and plated on VN in E8 medium. CTG was used to quantify viable cells 24 h post-seeding.
Chroman 1 purchased from MedChemExpress. Usage Cited in: Nat Methods. 2021 May;18(5):528-541. [Abstract]
Chroman 1 (50 nM; 24 h). Total caspase-3 expression in hESCs (WA09) in comparison to their lineage-committed precursors after directed differentiation into ectoderm (PAX6), mesoderm (Brachyury), and endoderm (SOX17). Note that caspase-3 is strongly expressed in the pluripotent state and downregulated upon differentiation.
-
Immunity
Microglial lipid phosphatase SHIP1 limits complement-mediated synaptic pruning in the healthy developing hippocampus. [Abstract]2024 Dec 6:S1074-7613(24)00513-2. PMID: 39657671 -
Cell Stem Cell
An inducible model of human post-implantation development derived from primed and naive stem cells. [Abstract]2025 Oct 2;32(10):1509-1527.e9. PMID: 40885193 -
Mol Cell
Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1. [Abstract]2023 Jul 20;83(14):2398-2416.e12. PMID: 37402365 -
ACS Nano
Reproducible Human Neural Circuits Printed with Single-Cell Precision Reveals the Functional Roles of Ephaptic Coupling. [Abstract]2025 Oct 26. PMID: 41139300 -
Nat Protoc
Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail. [Abstract]2023 Jan;18(1):58-80. PMID: 36261632
Chroman 1 purchased from MedChemExpress. Usage Cited in: Nat Protoc. 2023 Jan;18(1):58-80. [Abstract]
Chroman 1 (50 nM; 5 min). Fast-acting CEPT (Chroman 1, Emricasan, Polyamines, trans-ISRIB) is cytoprotective and maintains cell morphology of WA09 dissociated cells, whereas ongoing cell contractions lead to abnormal cells in the presence of Y-27632.
-
Nat Commun
2025 May 28;16(1):4945. PMID: 40436823 -
Exp Hematol Oncol
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors. [Abstract]2025 Mar 1;14(1):26. PMID: 40025520 -
Nat Struct Mol Biol
2026 Apr;33(4):631-640. PMID: 41951886 -
Acta Neuropathol
2024 Mar 13;147(1):56. PMID: 38478117 -
Cell Rep
Triglyceride metabolism controls inflammation and microglial phenotypes associated with APOE4. [Abstract]2025 Jul 10;44(7):115961. PMID: 40644302 -
Cell Rep
Establishment of bovine extraembryonic endoderm stem cells enables efficient blastoid formation. [Abstract]2025 May 20;44(6):115707. PMID: 40402743 -
Cell Rep
iPSC motor neurons, but not other derived cell types, capture gene expression changes in postmortem sporadic ALS motor neurons. [Abstract]2023 Aug 30;42(9):113046. PMID: 37651231 -
-
Stem Cell Reports
2023 Apr 11;18(4):1030-1047. PMID: 37044067 -
Cell Regen
Neuroligin-3 R451C induces gain-of-function gene expression in astroglia in an astroglia-enriched brain organoid model. [Abstract]2025 Jan 8;14(1):1. PMID: 39775628 -
Bioorg Chem
Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]2024 Jun:147:107412. PMID: 38696845 -
J Med Virol
The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses. [Abstract]2024 Apr;96(4):e29579. PMID: 38572923
Chroman 1 purchased from MedChemExpress. Usage Cited in: J Med Virol. 2024 Apr;96(4):e29579. [Abstract]
Chroman 1 (50 nM; 24 h). Survivals of differentiated hiPSCs - anterior foregut endoderm (left) and AOs (right) were improved with CEPT cocktail (Chroman 1, Emricasan, Polyamines and trans-ISRIB) treatment compared to Y27632. Phase contrast images were taken after 24 h of seeding (hiPSC) and 8 days of seeding (AOs).
-
Cell Rep Methods
2024 Aug 27:100843. PMID: 39216483 -
iScience
2026 Jun 1;29(6):116143. PMID: 42291199 -
iScience
Highly efficient generation of self-renewing trophoblast from human pluripotent stem cells. [Abstract]2024 Sep 3;27(10):110874. PMID: 39386760 -
Sci Rep
Compact Calm1 promoter enables AAV mediated neuron-targeted expression in human iPSC-derived brain organoids. [Abstract]2025 Dec 24;15(1):44450. PMID: 41444788 -
Dis Model Mech
Human induced pluripotent stem cell-derived inner ear organoids reveal hair cell damage and plasticity after cisplatin and gentamicin exposure. [Abstract]2026 Jun 1;19(6):dmm052511. PMID: 41773293 -
Cytotherapy
Good Manufacturing Practice-compliant human induced pluripotent stem cells: from bench to putative clinical products. [Abstract]2024 Jun;26(6):556-566. PMID: 38483359 -
Mol Biol Cell
A system for high-throughput axonal imaging of induced pluripotent stem cell-derived human i3Neurons. [Abstract]2025 Dec 3:mbcE25060300. PMID: 41337653 -
Regen Med
International evaluation study of a highly efficient culture assay for detection of residual human pluripotent stem cells in cell therapies. [Abstract]2023 Mar;18(3):219-227. PMID: 36852420 -
STAR Protoc
Protocol for purifying primitive neural progenitors by fractional passaging to generate astroglia-enriched cerebral organoid. [Abstract]2025 Oct 13;6(4):104142. PMID: 41091601 -
STAR Protoc
Protocol for generating human craniofacial cartilage organoids from stem-cell-derived neural crest cells. [Abstract]2024 Dec 20;6(1):103532. PMID: 39708322 -
STAR Protoc
Generation of iPSC-based human-mouse microglial brain chimeras to study senescence of human microglia. [Abstract]2022 Dec 16;3(4):101847. PMID: 36595906 -
bioRxiv
Systemic degradation of repressive transcription factors gates gene expression and cell fate specification. [Abstract]2026 Jun 18:2026.06.16.732780. PMID: 42367945 -
bioRxiv
Combinatorial and Inducible CRISPRa/i Enables Canalized hiPSC Forward Programming and Iterative Refinement via Single-Cell Genomics. [Abstract]2026 Jun 1:2026.05.31.729073. PMID: 42282825 -
-
bioRxiv
Efficient Generation of Functional TCRαβ+ Cytotoxic T Cells from hiPSCs via Small-Molecule Modulation. [Abstract]2026 Apr 1:2026.03.31.715684. PMID: 41959015 -
-
bioRxiv
Female iPSC X-chromosome inactivation (XCI) erosion and its transcriptomic effects during CRISPR gene editing and neural differentiation. [Abstract]2026 Mar 1:2026.02.27.708613. PMID: 41890091 -
bioRxiv
Neuronal Cell-Cycle Re-entry Defines Divergent Outcomes Through Replication-Dependent DNA Damage in ALS. [Abstract]2026 Feb 16:2026.02.13.705790. PMID: 41756973 -
-
bioRxiv
2026 Jan 15:2026.01.14.699349. PMID: 41648576 -
-
-
bioRxiv
2025 Nov 6:2025.11.05.685987. PMID: 41278640 -
-
-
bioRxiv
Parallelized Brightfield and Fluorescence Imaging of Organoids Using a Scalable Multi-Camera Platform. [Abstract]2025 Oct 8:2025.10.07.681020. PMID: 41279238 -
-
bioRxiv
Morphogen-guided neocortical organoids recapitulate regional areal identity and model neurodevelopmental disorder pathology. [Abstract]2025 Sep 3:2025.09.02.672952. PMID: 40950130 -
-
bioRxiv
2025 Jul 14:2025.06.22.660773. PMID: 40667053 -
-
bioRxiv
2025 Feb 19:2025.02.18.638932. PMID: 40027688 -
bioRxiv
Temporal dynamics of proteome and phosphorproteome during neuronal differentiation in the reference KOLF2.1J iPSC line. [Abstract]2025 Mar 26:2025.03.25.645331. PMID: 40568166 -
bioRxiv
Proteomic Analysis of Endemic Viral Infections in Neurons offers Insights into Neurodegenerative Diseases. [Abstract]2025 Mar 17:2025.03.17.643709. PMID: 40166347 -
bioRxiv
Altered mRNA transport and local translation in iNeurons with RNA binding protein knockdown. [Abstract]2024 Sep 27:2024.09.26.615153. PMID: 39386562 -
bioRxiv
2024 Dec 4:2024.12.03.626438. PMID: 39677822 -
bioRxiv
2025 Jun 30:2024.09.30.615241. PMID: 39803527 -
bioRxiv
High-Complexity Barcoded Rabies Virus for Scalable Circuit Mapping Using Single-Cell and Single-Nucleus Sequencing. [Abstract]2024 Dec 11:2024.10.01.616167. PMID: 39713304 -
bioRxiv
Satellite glial contact enhances differentiation and maturation of human iPSC-derived sensory neurons. [Abstract]2024 Jul 24:2024.07.24.604966. PMID: 39211268 -
-
-
-
Res Sq
2023 Oct 19:rs.3.rs-3462973. PMID: 37886540 -
Res Sq
Anti-apoptotic treatment of warm ischemic male rat livers in machine perfusion improves symptoms of ischemia-reperfusion injury. [Abstract]2023 Aug 22:rs.3.rs-3260870. PMID: 37674730 -
Methods Mol Biol
2024:2767:1-18. PMID: 37351840 -
-
-
Methods Mol Biol
Human Pluripotent Stem Cells for High-Throughput Drug Screening and Characterization of Small Molecules. [Abstract]2022:2454:811-827. PMID: 34128205 -
bioRxiv
Robotic High-Throughput Biomanufacturing and Functional Differentiation of Human Pluripotent Stem Cells. [Abstract]2020 Aug 3:2020.08.03.235242. PMID: 32793899
溶剤 & 溶解度
DMSO : ≥ 50 mg/mL (114.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2910 mL | 11.4548 mL | 22.9095 mL | 57.2738 mL |
| 5 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL | 11.4548 mL | |
| 10 mM | 0.2291 mL | 1.1455 mL | 2.2910 mL | 5.7274 mL | |
| 15 mM | 0.1527 mL | 0.7637 mL | 1.5273 mL | 3.8183 mL | |
| 20 mM | 0.1145 mL | 0.5727 mL | 1.1455 mL | 2.8637 mL | |
| 25 mM | 0.0916 mL | 0.4582 mL | 0.9164 mL | 2.2910 mL | |
| 30 mM | 0.0764 mL | 0.3818 mL | 0.7637 mL | 1.9091 mL | |
| 40 mM | 0.0573 mL | 0.2864 mL | 0.5727 mL | 1.4318 mL | |
| 50 mM | 0.0458 mL | 0.2291 mL | 0.4582 mL | 1.1455 mL | |
| 60 mM | 0.0382 mL | 0.1909 mL | 0.3818 mL | 0.9546 mL | |
| 80 mM | 0.0286 mL | 0.1432 mL | 0.2864 mL | 0.7159 mL | |
| 100 mM | 0.0229 mL | 0.1145 mL | 0.2291 mL | 0.5727 mL |